• Mirati Therapeutics Announces Presentation Of Interim Phase 2 Sitravatinib Data In Urothelial Carcinoma And Oral Cavity Squamous Cell Carcinoma At The SITC 34th Annual Meeting

    26 days ago - By San Diego Biotechnology

    SAN DIEGO, Oct. 23, 2019 /PRNewswire/ - Mirati Therapeutics, Inc. , a clinical-stage targeted oncology company, announced that the Company will have two presentations at the Society for Immunotherapy of Cancer 34th Annual Meeti......
    Read more ...